MBG453
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
What's the purpose of the trial?
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS).
The name of the study drug involved in this study is MBG453.
Trial status
Accepting patients
Phase
Phase 2
Enrollment
20
Last Updated
1 month ago
Participating Centers
There are 3 centers participating in this trial. Enter a location below to find the closet center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Sabatolimab is a kind of drug called a TIM-3 monoclonal antibody that targets the TIM-3 protein found on the surface of several different types of cells in the immune system.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.